Jean-Daniel Lelièvre is professor in clinical immunology and head a department of clinical immunology and infectious diseases in Paris. His basic research was focused initially on T cell apoptosis during HIV infection and moved after on the biology of Treg during HIV infection and basic aspects of T-cell development and their disturbance during HIV infection.
Pr JD Lelièvre conducted several clinical trials in the field of immune-based therapies of HIV or vaccinology (role of treatment optimization with anti CCR5 in late diagnosis HIV + patients; role of raltegravir during kidney transplantation, IL7 treatment during HIV infection). For several years his research and expertise activity has been refocused on the field of vaccinology. He is in the charge of the clinical core of the VRI (Vaccine Research Institute) and of the WP 8 (prophylactic vaccine) of EHVA (European HIV Vaccine Alliance) both of which aim to promote a comprehensive approach to the development of an effective HIV vaccine.
In addition, his activities in the field of vaccines include the responsibility of a WP within the EU-JAV (European Joint Action on Vaccination) and Vaccelerate (dedicated to COVID19 vaccine) and national (French NITAG) and international expertise activities (WHO IVIR-AC, SAG EMA).
